Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS

被引：0
|
作者：
Lipton, R. B. [1 ]
Chalermpalanupap, N. [2 ]
Tatsuoka, Y. [3 ]
Nagy, K. [4 ]
Liu, Y. [5 ]
Carr, K. [5 ]
McAllister, P. [6 ]
Nahas, S. J. [7 ]
Trugman, J. M. [2 ]
Sacco, S. [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, MA USA
[2] AbbVie, Madison, NJ USA
[3] Tatsuoka Neurol Clin, Kyoto, Japan
[4] AbbVie, Budapest, Hungary
[5] AbbVie, N Chicago, IL USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[8] Univ Aquila, Laquila, Italy
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P036
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
    Ferrari, Michel D.
    Zuurbier, Karin W. M.
    Barash, Steve
    Ning, Xiaoping
    Cohen, Joshua M.
    HEADACHE, 2022, 62 (04): : 530 - 533
  • [42] Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure: Post hoc DELIVER analyses
    Pozo-Rosich, Patricia
    Ashina, Messoud
    Tepper, Stewart J.
    Jensen, Sidsel
    Boserup, Line Pickering
    Josiassen, Mette Krog
    Sperling, Bjorn
    CEPHALALGIA, 2023, 43 (1supp) : 227 - 227
  • [43] Predictors of Inadequate 24-Hour Sustained Response in Episodic Migraine: Results from American Migraine Prevalence and Prevention Study (PP)
    Munjal, Sagar
    Reed, Michael
    Buse, Dawn
    Bennett, Alexandre
    Fanning, Kristina
    Lipton, Richard
    NEUROLOGY, 2016, 86
  • [44] Predictors of Inadequate 24-Hour Sustained Response in Episodic Migraine: Results from American Migraine Prevalence and Prevention Study (AMPP)
    Munjal, Sagar
    Reed, Michael
    Buse, Dawn
    Bennett, Alexandre
    Fanning, Kristina
    Lipton, Richard
    NEUROLOGY, 2016, 86
  • [45] Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
    Paul Rizzoli
    Michael J. Marmura
    Jennifer Robblee
    Jennifer McVige
    Sara Sacco
    Stephanie J. Nahas
    Jessica Ailani
    Rosa De Abreu Ferreira
    Julia Ma
    Jonathan H. Smith
    Brett Dabruzzo
    Messoud Ashina
    The Journal of Headache and Pain, 25
  • [46] Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
    Rizzoli, Paul
    Marmura, Michael J.
    Robblee, Jennifer
    Mcvige, Jennifer
    Sacco, Sara
    Nahas, Stephanie J.
    Ailani, Jessica
    De Abreu Ferreira, Rosa
    Ma, Julia
    Smith, Jonathan H.
    Dabruzzo, Brett
    Ashina, Messoud
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [47] Reversion from chronic to episodic migraine in patients with inadequate response to 2-4 classes of migraine preventive treatments in the focus phase 3b study
    Lipton, R. B.
    Ailani, J.
    Ramirez-Campos, V.
    Cohen, J. M.
    Yang, R.
    Galic, M.
    Ning, X.
    Singh, R. Halker
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [48] Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
    Vernieri, F.
    Gandhi, P.
    Ashina, M.
    Seng, E.
    Lipton, R. B.
    Nagy, K.
    Liu, Y.
    Carr, K.
    Stokes, J.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [49] Long-term Tolerability and Improvements in Disability and Quality of Life With Fremanezumab in Patients With Chronic or Episodic Migraine and Documented Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications
    Buse, D. C.
    Cohen, J. M.
    Campos, V. Ramirez
    Ning, X.
    Janka, L.
    Mechtler, L.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 118 - 118
  • [50] Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
    Doty, Erin Gautier
    Krege, John H.
    Jin, Leah
    Raskin, Joel
    Singh, Rashmi B. Halker
    Kalidas, Kavita
    CEPHALALGIA, 2019, 39 (12) : 1569 - 1576
12345